Safety and Efficacy Study of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00947687
Recruitment Status : Completed
First Posted : July 28, 2009
Last Update Posted : September 19, 2017
Retroscreen Virology Ltd.
Quintiles, Inc.
Information provided by (Responsible Party):
Pulmatrix Inc.

July 24, 2009
July 28, 2009
September 19, 2017
July 2009
September 2009   (Final data collection date for primary outcome measure)
Safety and tolerability of PUR003 as determined by incidence of adverse events (AEs); changes in physical examination, chest examination; pulmonary function; vital signs; electrocardiogram (ECG) and clinical laboratory assessments. [ Time Frame: Day 6 ]
Same as current
Complete list of historical versions of study NCT00947687 on Archive Site
  • Subjected-reported symptom scores assessed both individually and as a composite score evaluating severity overall and at the time of peak symptom score [ Time Frame: Day 6 of study ]
  • Quantitative viral shedding from nasal viral inoculation until day 6 [ Time Frame: Day 0 to day 6 ]
  • Change in bioaerosol output with treatment and after viral inoculation [ Time Frame: Day -2 to day 6 ]
Same as current
Not Provided
Not Provided
Safety and Efficacy Study of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects
A Randomized, Phase 1B, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects
The objectives of the study are to demonstrate the effectiveness, safety and tolerability of multiple daily doses of inhaled PUR003, in comparison with placebo, in healthy adults experimentally inoculated with Influenza A/Wisconsin/67/2005 (H3N2) virus.
Not Provided
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Drug: PUR003
    Twice-daily (BID) doses of PUR003 will be delivered via inhalation using a commercially available nebulizer for a total of 7 days
  • Drug: Placebo
  • Experimental: PUR003
    Intervention: Drug: PUR003
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
October 2009
September 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and female subjects aged 18 to 45 years.
  • In general good health determined by a screening evaluation ≤120 days prior to double-blind IMP administration and on the day of admittance to quarantine.
  • Seronegative (NDA) for challenge virus.
  • Have not been vaccinated for influenza virus since 2006 (as determined in the medical history) or had a known influenza infection in the current season, defined as in the last 12 months.

Exclusion Criteria:

  • Presence or evidence of significant acute or chronic, uncontrolled medical or psychiatric illness.
  • Abnormal pulmonary function as evidenced by clinically significant abnormality in spirometry.
  • Health care workers (including doctors, nurses, medical students and allied healthcare professionals) anticipated to have patient contact within two weeks of discharge from quarantine.
  • Intending to travel (to countries for which vaccinations are recommended or where high risk of infections exists).
  • Presence of household member or close contact (until 14 days after discharge from quarantine) who is: less than 3 years of age; has any known immunodeficiency; is receiving immunosuppressant medications; is undergoing or soon to undergo cancer chemotherapy within 28 days of challenge.
  • Subjects with diagnosed emphysema or chronic obstructive pulmonary disease (COPD); elderly residing in a nursing home, affected by severe lung disease or medical condition; or a transplant (bone marrow or solid organ) organ recipient
  • Subjects with any history of asthma, COPD, pulmonary hypertension, reactive airway disease, or any chronic lung condition of any aetiology.
  • Regular daily smokers during the 6 months prior to study entry or those who have a significant history of any tobacco use at any time (≥ total 10 pack year history = one pack a day for 10 years).
  • Presence of any febrile illness or symptoms of upper or lower tract respiratory infection in the 28 days prior to viral inoculation (such subjects may be re-evaluated for enrolment after resolution of the illness).
  • Receipt of any investigational drug within 3 months, or prior participation in a clinical trial of any influenza vaccine or medication within 1 year of participation.
Sexes Eligible for Study: All
18 Years to 45 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United Kingdom
Not Provided
Not Provided
Pulmatrix Inc.
Pulmatrix Inc.
  • Retroscreen Virology Ltd.
  • Quintiles, Inc.
Study Director: John P Hanrahan, MD Pulmatrix Inc.
Pulmatrix Inc.
September 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP